See more : M3-Brigade Acquisition III Corp. (MBSC) Income Statement Analysis – Financial Results
Complete financial analysis of Microbio Co., Ltd. (4128.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbio Co., Ltd., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- Shenzhen Das Intellitech Co., Ltd. (002421.SZ) Income Statement Analysis – Financial Results
- Alpine Income Property Trust, Inc. (PINE) Income Statement Analysis – Financial Results
- Macondray Capital Acquisition Corp. I (DRAYU) Income Statement Analysis – Financial Results
- Ratos AB (publ) (RATO-A.ST) Income Statement Analysis – Financial Results
- Domo Activos, S.A. (DOMO.MC) Income Statement Analysis – Financial Results
Microbio Co., Ltd. (4128.TWO)
About Microbio Co., Ltd.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.59B | 1.72B | 1.78B | 1.60B | 1.47B | 1.45B | 1.41B | 1.52B | 1.52B | 1.40B | 1.17B | 1.18B | 1.19B | 1.08B | 737.67M | 512.59M | 155.60M | 231.53M |
| Cost of Revenue | 987.51M | 1.03B | 1.04B | 967.67M | 886.25M | 877.98M | 891.87M | 941.62M | 943.61M | 829.30M | 706.55M | 670.67M | 596.32M | 522.19M | 405.68M | 287.42M | 83.56M | 127.66M |
| Gross Profit | 603.88M | 691.30M | 739.37M | 633.73M | 580.06M | 570.55M | 520.92M | 580.82M | 575.25M | 570.05M | 461.29M | 506.99M | 598.47M | 556.93M | 332.00M | 225.17M | 72.05M | 103.87M |
| Gross Profit Ratio | 37.95% | 40.15% | 41.49% | 39.57% | 39.56% | 39.39% | 36.87% | 38.15% | 37.87% | 40.74% | 39.50% | 43.05% | 50.09% | 51.61% | 45.01% | 43.93% | 46.30% | 44.86% |
| Research & Development | 404.49M | 264.91M | 861.54M | 352.97M | 98.16M | 40.10M | 87.60M | 181.88M | 178.14M | 231.61M | 241.29M | 165.60M | 132.30M | 136.68M | 87.59M | 59.50M | 25.89M | 24.71M |
| General & Administrative | 186.25M | 169.36M | 474.88M | 827.44M | 180.96M | 190.26M | 188.19M | 166.56M | 198.02M | 197.84M | 207.96M | 210.83M | 204.78M | 120.46M | 86.10M | 76.02M | 34.05M | 34.64M |
| Selling & Marketing | 519.62M | 536.69M | 566.06M | 559.27M | 462.20M | 472.67M | 490.70M | 501.81M | 541.68M | 528.15M | 421.05M | 561.62M | 644.57M | 504.48M | 292.48M | 231.94M | 112.00M | 52.47M |
| SG&A | 705.86M | 706.05M | 1.04B | 1.39B | 643.16M | 662.93M | 678.89M | 668.37M | 739.71M | 725.99M | 629.01M | 772.45M | 849.36M | 624.94M | 378.57M | 307.95M | 146.05M | 87.11M |
| Other Expenses | 0.00 | -817.00K | -1.73M | -1.45M | 66.00K | -21.98M | 801.10M | -66.43M | 71.49M | 104.33M | 207.17M | 36.95M | 245.95M | 14.85M | 12.13M | -29.80M | -17.79M | -13.26M |
| Operating Expenses | 886.89M | 970.15M | 1.90B | 1.74B | 741.39M | 703.03M | 766.49M | 850.25M | 917.85M | 957.60M | 870.29M | 938.04M | 981.65M | 761.62M | 466.16M | 367.17M | 171.83M | 112.20M |
| Cost & Expenses | 2.10B | 2.00B | 2.94B | 2.71B | 1.63B | 1.58B | 1.66B | 1.79B | 1.86B | 1.79B | 1.58B | 1.61B | 1.58B | 1.28B | 871.84M | 654.59M | 255.39M | 239.86M |
| Interest Income | 89.11M | 42.75M | 36.31M | 55.54M | 73.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.63M | 36.68M | 17.39M | 9.82M | 18.99M | 3.97M | 2.73M |
| Interest Expense | 7.38M | 6.10M | 6.22M | 7.33M | 9.48M | 2.83M | 6.79M | 7.07M | 7.06M | 2.08M | 8.03M | 1.12M | 1.38M | 5.08M | 6.96M | 15.68M | 10.88M | 7.17M |
| Depreciation & Amortization | 245.17M | 242.25M | 269.27M | 210.49M | 189.87M | 62.80M | 81.84M | 95.77M | 110.21M | 100.96M | 94.42M | 101.19M | 81.05M | 51.32M | 44.83M | 36.98M | 23.23M | 32.17M |
| EBITDA | -1.13B | 164.23M | -675.82M | -914.47M | -97.00M | -91.65M | 637.37M | -240.09M | -163.91M | -182.36M | -107.42M | -50.09M | 444.75M | 542.67M | -12.55M | 109.51M | -89.37M | 15.23M |
| EBITDA Ratio | -70.70% | 23.25% | 2.50% | 46.14% | -3.74% | -45.68% | 41.37% | -14.79% | -9.34% | -11.30% | -4.34% | -21.52% | -1.49% | -12.80% | -8.71% | -22.56% | -57.44% | 6.58% |
| Operating Income | -506.47M | 157.92M | -225.65M | 526.75M | -244.99M | -132.48M | -245.57M | -269.43M | -342.61M | -387.54M | -409.01M | -431.06M | -383.19M | -204.70M | -134.17M | -142.00M | -99.79M | -8.33M |
| Operating Income Ratio | -31.83% | 9.17% | -12.66% | 32.89% | -16.71% | -9.15% | -17.38% | -17.70% | -22.56% | -27.69% | -35.02% | -36.60% | -32.07% | -18.97% | -18.19% | -27.70% | -64.13% | -3.60% |
| Total Other Income/Expenses | -871.40M | -6.10M | -6.22M | 1.63B | -93.68M | -595.14M | 737.26M | -62.17M | 83.51M | 126.36M | 255.89M | 241.09M | 745.50M | 690.97M | 69.83M | 198.85M | -23.47M | -15.77M |
| Income Before Tax | -1.38B | 151.83M | -231.87M | 519.42M | -255.01M | -727.61M | 491.69M | -331.60M | -259.09M | -261.18M | -153.12M | -26.30M | 365.55M | 485.75M | -64.34M | 56.85M | -123.48M | -24.10M |
| Income Before Tax Ratio | -86.58% | 8.82% | -13.01% | 32.44% | -17.39% | -50.23% | 34.80% | -21.78% | -17.06% | -18.66% | -13.11% | -2.23% | 30.60% | 45.01% | -8.72% | 11.09% | -79.35% | -10.41% |
| Income Tax Expense | -553.00K | -598.00K | 1.29M | -418.00K | 9.59M | 9.84M | 9.80M | 10.35M | 16.66M | -46.15M | 5.16M | 5.54M | 80.56M | 66.46M | 13.67M | 12.97M | -12.87M | -8.62M |
| Net Income | -1.18B | 152.42M | -233.16M | 519.84M | -264.60M | -690.74M | 543.03M | -267.82M | -193.69M | -140.43M | -129.12M | -33.29M | 280.37M | 412.53M | -81.77M | 25.94M | -123.43M | -24.09M |
| Net Income Ratio | -74.14% | 8.85% | -13.08% | 32.46% | -18.05% | -47.69% | 38.44% | -17.59% | -12.75% | -10.04% | -11.06% | -2.83% | 23.47% | 38.23% | -11.08% | 5.06% | -79.32% | -10.40% |
| EPS | -2.11 | 0.27 | -0.43 | 1.00 | -0.49 | -1.23 | 0.97 | -0.48 | -0.35 | -0.25 | -0.27 | -0.07 | 0.61 | 0.90 | -0.29 | 0.11 | -0.77 | -0.17 |
| EPS Diluted | -2.11 | 0.27 | -0.43 | 1.00 | -0.49 | -1.23 | 0.97 | -0.48 | -0.35 | -0.25 | -0.27 | -0.07 | 0.61 | 0.90 | -0.29 | 0.11 | -0.77 | -0.17 |
| Weighted Avg Shares Out | 559.18M | 559.85M | 545.95M | 521.05M | 544.47M | 561.09M | 562.18M | 561.10M | 559.66M | 558.45M | 480.08M | 451.23M | 458.10M | 457.44M | 282.85M | 235.40M | 160.25M | 144.18M |
| Weighted Avg Shares Out (Dil) | 560.16M | 559.89M | 545.96M | 521.05M | 544.47M | 562.17M | 562.34M | 562.18M | 560.73M | 559.52M | 481.00M | 452.46M | 459.97M | 458.49M | 282.85M | 236.47M | 160.25M | 144.18M |
Source: https://incomestatements.info
Category: Stock Reports